Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Viusid and Asbrip in COVID-19
NCT04980534Completed
- Start
- Jan 2021
- Primary completion
- Jun 2021
- Countries
- 1
01
Overview
Randomised, open-label trial (3 arms). Primary endpoint: Mean duration of hospitalization at 21 days. Started Jan 2021; status: completed.
Beyond the preview
Go deeper on NCT04980534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04980534.